DOCSLIB.ORG

Friday, September 16, 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Friday, September 16, 2016 Friday, September 16, 2016 FRIDAY,SEPTEMBER 16, 2016 DAY-AT-A-GLANCE Time/Event/Location All locations in the Georgia World Congress Center unless otherwise noted 6:00 am - 8:00 am . .. .. .. .. .. ................................................................... 3 ASBMR Clinical Breakfast: How Discoveries Lead to Treatment of Rare Bone Diseases Room A302 7:00 am - 7:00 pm . .. .. .. .. .. ................................................................... 3 ASBMR Registration Open Registration Hall - Main Entrance 8:00 am - 9:30 am . .. .. .. .. .. ................................................................... 3 Gerald D. Aurbach Lecture and the Presentation of the William F. Neuman and Friday Lawrence G. Raisz Awards Thomas B. Murphy Ballroom - Building B Level 5 9:30 am - 10:00 am . .. .. .. .. .. ................................................................... 3 Networking Break Murphy Ballroom Foyer - Building B 10:00 am - 11:30 am.. .. .. .. .. ................................................................... 4 Highlights of the ASBMR 2016 Annual Meeting Thomas B. Murphy Ballroom - Building B Level 5 10:00 am - 11:30 am.. .. .. .. .. ................................................................... 4 Grant Writing Workshop: What to Choose and How to Fund It Room A302 10:45 am - 11:45 am.. .. .. .. .. ................................................................... 4 Meet-The-Professor Sessions Rooms A311-316 11:30 am - 12:00 pm . .. .. .. .. ................................................................... 5 Networking Break Murphy Ballroom Foyer Building B and Sidney Marcus Foyer Building A 12:00 pm - 1:15 pm. .. .. .. .. .. ................................................................... 5 Symposium-EPO in Bone Physiology and Disease Thomas B. Murphy Ballroom - Building B Level 5 12:00 pm - 1:15 pm. .. .. .. .. .. ................................................................... 6 Symposium-The Importance of Cortical Bone Through the Life Span Sidney Marcus Auditorium - Building A 1:15 pm - 1:45 pm. .. .. .. .. .. ................................................................... 6 Networking Break Murphy Ballroom Foyer Building B and Sidney Marcus Foyer Building A 1:45 pm - 2:45 pm. .. .. .. .. .. ................................................................... 6 Concurrent Orals: Mechanisms of Bone and Joint Disease Room A404/405 1:45 pm - 2:45 pm. .. .. .. .. .. ................................................................... 7 Concurrent Orals: Osteoporosis Treatment I Sidney Marcus Auditorium - Building A 1:45 pm - 2:45 pm. .. .. .. .. .. ................................................................... 8 Concurrent Orals: Rare Bone Disease (Translational) Room A402/403 1 1:45 pm - 2:45 pm. .. .. .. .. .. ................................................................... 9 Concurrent Orals: Sclerostin Regulation and Function Room A411/412 2:45 pm - 3:00 pm. .. .. .. .. .. .................................................................. 10 Networking Break 3:00 pm - 4:00 pm. .. .. .. .. .. .................................................................. 10 Concurrent Orals: Aging Room A404/405 3:00 pm - 4:00 pm. .. .. .. .. .. .................................................................. 11 Concurrent Orals: Biomechanics and Bone Quality Room A411/412 3:00 pm - 4:00 pm. .. .. .. .. .. .................................................................. 12 Concurrent Orals: Chondrocyte Biology and Development Room A402/403 3:00 pm - 4:00 pm. .. .. .. .. .. .................................................................. 13 Concurrent Orals: Genetics and Genomics Sidney Marcus Auditorium - Building A 4:00 pm - 4:30 pm. .. .. .. .. .. .................................................................. 14 Networking Break Murphy Ballroom Foyer Building B and Sidney Marcus Foyer Building A 4:30 pm - 5:30 pm. .. .. .. .. .. .................................................................. 14 ASBMR/ECTS Clinical Debate-Microdamage Is Good for Bone Thomas B. Murphy Ballroom - Building B Level 5 4:30 pm - 5:30 pm. .. .. .. .. .. .................................................................. 14 Symposium-Matricellular Proteins Sidney Marcus Auditorium - Building A 5:30 pm - 7:00 pm. .. .. .. .. .. .................................................................. 15 Young Investigator and New Member Reception ASBMR Discovery Hall - Expo Hall A1 5:30 pm - 7:00 pm. .. .. .. .. .. .................................................................. 15 Welcome Reception & Plenary Poster Session ASBMR Discovery Hall - Expo Hall A1 7:15 pm - 8:00 pm. .. .. .. .. .. .................................................................. 40 Young Investigator and Diverse Member Networking Hour Omni Atlanta Hotel at CNN Center, International Ballroom A 7:15 pm - 9:45 pm. .. .. .. .. .. .................................................................. 40 Muscle and Bone Working Group Room A302 7:15 pm - 9:00 pm. .. .. .. .. .. .................................................................. 41 Nutrition and Bone Working Group Room A303 7:15 pm - 9:45 pm. .. .. .. .. .. .................................................................. 41 Rare Bone Disease Working Group Room 311 7:15 pm - 9:45 pm. .. .. .. .. .. .................................................................. 42 Working Group on Aging Room A315 7:30 pm - 9:30 pm. .. .. .. .. .. .................................................................. 42 Bone Turnover Markers Working Group Room A305 8:00 pm - 9:30 pm. .. .. .. .. .. .................................................................. 42 Women’s Committee Networking Reception Omni Atlanta Hotel at CNN Center, International Ballroom C 2 ASBMR CLINICAL BREAKFAST: HOW DISCOVERIES LEAD TO TREATMENT OF RARE BONE DISEASES Supported by Educational Grants from Alexion Pharmaceuticals, Shire and Ultragenyx Pharmaceuticals, Inc. 6:00 am - 8:00 am Georgia World Congress Center Room A302 Chair Eileen Shore, Ph.D. University of Pennsylvania, USA Disclosures: Eileen Shore, None 6:00 am Breakfast 6:30 am Hypoparathyroidism Dolores Shoback, M.D. VA Medical Center, USA Disclosures: Dolores Shoback, None Friday 7:00 am Hypophosphatasia Michael Whyte, M.D. Shriners Hospital for Children, USA Disclosures: Michael Whyte, None 7:30 am XLH in Adults Karl Insogna, M.D. Yale University School of Medicine, USA Disclosures: Karl Insogna, Ultragenyx 13 ASBMR REGISTRATION OPEN 7:00 am - 7:00 pm Georgia World Congress Center Registration Hall - Main Entrance GERALD D. AURBACH LECTURE AND THE PRESENTATION OF THE WILLIAM F. NEUMAN AND LAWRENCE G. RAISZ AWARDS 8:00 am - 9:30 am Georgia World Congress Center Thomas B. Murphy Ballroom - Building B Level 5 8:00 am Personalized Medicine: Using omics Profiling and Big Data to Understand and Manage Health and Disease Michael Snyder, Ph.D. Stanford University, USA Disclosures: Michael Snyder, None NETWORKING BREAK 9:30 am - 10:00 am Georgia World Congress Center Murphy Ballroom Foyer - Building B 3 HIGHLIGHTS OF THE ASBMR 2016 ANNUAL MEETING Dedicated to the memory of Betsy L. McClung 10:00 am - 11:30 am Georgia World Congress Center Thomas B. Murphy Ballroom - Building B Level 5 This special session is of interest to all health professionals, first-time meeting attendees, young investigators, individuals new to the field, nurses, clinical research study coordinators, physical therapists and/or those seeking guidance in navigating through the extensive ASBMR program. 10:00 am Basic Science Meeting Overview Roland Baron, DDS, PhD Harvard Medical School and School of Dental Medicine, USA Disclosures: Roland Baron, None 10:45 am Clinical Science Meeting Overview John Bilezikian, M.D. Columbia University College of Physicians and Surgeons, USA Disclosures: John Bilezikian, Radius 14; Merck 14; Shire 14; Amgen 14 GRANT WRITING WORKSHOP: WHAT TO CHOOSE AND HOW TO FUND IT Sponsored by the ASBMR Membership Engagement and Education Committee 10:00 am - 11:30 am Georgia World Congress Center Room A302 Join your fellow researchers and colleagues in this interactive session to discuss potential obstacles to grant writing and strategic ways to overcome them. The following topics will be covered in this unique, 90 minute session: New NIH Requirements, International Funding, and Choosing the Appropriate Grant Mechanism and/or Funding Agency. As an attendee, you’ll have the opportunity to participate in one or all of these discussions, as you choose. This is a can’tmiss opportunity for researchers at any career stage who want to gain valuable insight into getting their research funded. Co-Chairs Melissa Kacena, Ph.D. Indiana University School of Medicine, USA Disclosures: Melissa Kacena, None Stavroula Kousteni, Ph.D. Columbia University Medical Center, USA Disclosures: Stavroula Kousteni, None MEET-THE-PROFESSOR SESSIONS 10:45 am - 11:45 am Georgia World Congress Center Rooms A311-316 Meet the Professor: Using Medicare Claims Data to Study Fracture Epidemiology Room A311 Sarah Berry, M.D. Hebrew SeniorLife/Beth Israel Deaconess Medical Center, USA Disclosures: Sarah Berry, None Nicole Wright, Ph.D., MPH University of Alabama at Birmingham, USA Disclosures: Nicole Wright, Amgen 13 4 Meet the Professor: Advances in Osteoarthritis Imaging and Treatment Room A312 Nancy Lane, M.D. University of California, Davis Medical Center, USA Disclosures: Nancy Lane, None Sharmila Majumdar, Ph.D. University of California, San Francisco, USA Disclosures: Sharmila Majumdar, None Meet
Load more

Recommended publications
  • Troféu Julio De Lamare Campeonato Brasileiro Junior - 2013 Pq
    TROFÉU JULIO DE LAMARE CAMPEONATO BRASILEIRO JUNIOR - 2013 PQ. AQUATICO DO BOTAFOGO F.R. PISCINA 50 M 04/12/2013 à 07/12/2013 Resultados da Final Etapa: 1 Data: 04/12/2013 1ª PROVA 100 METROS COSTAS FEMININO - JUNIOR 1 04/12/2013 RM GEMNA SPOFFORHT GBR 00:58.12 28/07/2009 ROMA RS FABIOLA PULGA MOLINA BRA 01:00.07 02/08/2009 ROMA RB FABIOLA PULGA MOLINA BRA 01:00.07 02/08/2009 ROMA RC NATALIA DE LUCCAS CORINTHIANS/ABDEM 01:01.50 04/12/2013 PQ. AQUATICO DO BOTAFOGO Col. S R Nome Patrocínio Reg. Nasc. Entidade Tempo Pts. Índice RC RB RSRM Obtido 1º 1 4 NATALIA DE LUCCAS 114738 1996 CORINTHIANS/ABDEM 01:01.50 19,00 933 RC 50M: 00:30.02 100M: 01:01.50 2º 1 5 NICOLE CHABOT DE MENEZES MACHADO 091123 1996 PINHEIROS 01:05.41 7,00 838 50M: 00:31.74 100M: 01:05.41 3º 1 3 TATIANA ZAGO ADORNO 119248 1996 FIAT/MINAS 01:06.99 6,00 801 50M: 00:32.36 100M: 01:06.99 4º 1 6 ANA CATARINA KONDO 100062 1996 CURITIBANO 01:08.40 5,00 768 50M: 00:33.13 100M: 01:08.40 5º 1 1 ANA CAROLINA LUCIETTO 110041 1996 AAC-SEMEL- CASCAVEL- 01:08.43 4,00 767 50M: 00:33.39 100M: 01:08.43 6º 1 2 BIANCA RODRIGUES VIEIRA 094021 1996 CORINTHIANS/ABDEM 01:09.13 3,00 751 50M: 00:33.71 100M: 01:09.13 7º 1 7 LUANA NAKAYAMA PEDROSO 110034 1996 CURITIBANO 01:09.65 2,00 739 50M: 100M: 01:09.65 8º 1 8 ISABELLA DARTORA 110016 1996 CURITIBANO 01:11.00 1,00 709 50M: 00:33.83 100M: 01:11.00 2ª PROVA 100 METROS COSTAS FEMININO - JUNIOR 2 04/12/2013 RM GEMNA SPOFFORHT GBR 00:58.12 28/07/2009 ROMA RS FABIOLA PULGA MOLINA BRA 01:00.07 02/08/2009 ROMA RB FABIOLA PULGA MOLINA BRA 01:00.07 02/08/2009 ROMA RC ETIENE PIRES MEDEIROS NN SESI CPR/PE 01:03.79 19/12/2009 SÃO PAULO Tempo Col.
    [Show full text]
  • Are Nanodiamond-Encrusted Teeth the Future of Dental Implants? 18 September 2013, by Brianna Deane
    Are nanodiamond-encrusted teeth the future of dental implants? 18 September 2013, by Brianna Deane prosthetic joints or teeth, which leads to the implants becoming loose—or failing. Implant failures necessitate additional procedures, which can be painful and expensive, and can jeopardize the function the patient had gained with an implant. These challenges are exacerbated when the disease occurs in the mouth, where there is a limited supply of local bone that can be used to secure the prosthetic tooth, a key consideration for both functional and aesthetic reasons. The study, led by Dr. Dean Ho, professor of oral biology and medicine and co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry, Nanodiamonds. Credit: UCLA School of Dentistry appears online in the peer-reviewed Journal of Dental Research. During bone repair operations, which are typically (Medical Xpress)—UCLA researchers have costly and time-consuming, doctors insert a sponge discovered that diamonds on a much, much through invasive surgery to locally administer smaller scale than those used in jewelry could be proteins that promote bone growth, such as bone used to promote bone growth and the durability of morphogenic protein. dental implants. Ho's team discovered that using nanodiamonds to Nanodiamonds, which are created as byproducts deliver these proteins has the potential to be more of conventional mining and refining operations, are effective than the conventional approaches. The approximately four to five nanometers in diameter study found that nanodiamonds, which are invisible and are shaped like tiny soccer balls. to the human eye, bind rapidly to both bone morphogenetic protein and fibroblast growth factor, Scientists from the UCLA School of Dentistry, the demonstrating that the proteins can be UCLA Department of Bioengineering and simultaneously delivered using one vehicle.
    [Show full text]
  • PCT Gazette, Weekly Issue No. 29, 1998
    29/1998 23 Jul/juil 1998 PCT Gazette - Section I - Gazette du PCT 11497 SECTION I PUBLISHED INTERNATIONAL APPLICATIONS DEMANDES INTERNATIONALES PUBLIÉES 6 (11) WO 98/31208 (13) A1 (43) 23 Jul/juil 1998 (23.07.1998) (51) A01J 7/00 // 5/017, A01K 1/12, H05K 5/00 (51)6 A01C 5/06 (21) PCT/GB98/00026 (54) A DEVICE FOR A MILKING STALL DISPOSITIF DESTINE A UNE SALLE DE (54) PLANTING UNIT TRAITE (22) 14 Jan/jan 1998 (14.01.1998) UNITE DE PLANTATION (25) en (26) en (71) ALFA LAVAL AGRI AB [SE/SE]; P.O. Box 39, (71, 72) BAUGHER, Roger, D. [US/US]; P.O. Box S–147 21 Tumba (SE). 79–A, McClure, IL 62957 (US). BAUGHER, Gar- (for all designated States except / pour tous les États (31) 9700754.6 (32) 15 Jan/jan 1997 (33) GB reth, D. [US/US]; P.O. Box 79–A, McClure, IL désignés sauf US) (15.01.1997) 62957 (US). (72, 75) KULLBERG, Marianne, Kristina, (43) 23 Jul/juil 1998 (23.07.1998) (74) MATTHEWS, Stephen, R.; Haverstock, Garrett & Åkesdotter [SE/SE]; Östmarksgatan 36, S–123 6 Roberts, Suite 1610, 611 Olive Street, St. Louis, 42 Farsta (SE). GUSTAFSON, Percy, Birger, (51) A01B 35/24 MO 63101 (US). Kenneth [SE/SE]; Björknäsvägen 25, S–151 37 Södertälje (SE). (54) TINE FOR MOUNTING ON SOIL–WORKING (81) AL AM AT AU AZ BA BB BG BR BY CA CH IMPLEMENT CN CU CZ DE DK EE ES FI GB GE GH HU IL (74) BERGLUND, Stefan et al. / etc.; Bjerkéns DENT S’ADAPTANT SUR UN ENGIN DE TRA- IS JP KE KG KP KR KZ LC LK LR LS LT LU Patentbyrå KB, Östermalmsgatan 58, S–114 50 VAIL DU SOL LV MD MG MK MN MW MX NO NZ PL PT RO Stockholm (SE).
    [Show full text]
  • 2019-2020 UCLA Academic Senate Program Review of University Extension
    2019-2020 ACADEMIC SENATE PROGRAM REVIEW OF UNIVERSITY EXTENSION Internal Reviewers Olga T. Yokoyama, Humanities, Graduate Council, Review Team Chair Simon Board, Economics, Undergraduate Council External Reviewers Susan Greenbaum, Dean, Professional Studies, New York University John LaBrie, Dean, Professional Studies, Clark University Date of Site Visit: January 14-15, 2020 Approved by Undergraduate Council: April 10, 2020 Approved by Graduate Council: May 1, 2020 Appendix I: External Reviewers’ Report Appendix II: Site Visit Schedule Please note: The Self-Review report was previously distributed. If you need a copy, please contact the Academic Senate Office at [email protected]. 2019-2020 ACADEMIC SENATE PROGRAM REVIEW OF UNIVERSITY EXTENSION Introduction This report of the Internal Review Team for the 2019-2020 review of University Extension (UNEX) follows eight years after the prior Academic Senate Program Review of UNEX in 2011-2012. The current review draws primarily on a two-day site visit held on January 14-15, 2020, the prior Academic Senate Program Review Report from 2011-2012, the UNEX self-review of 2019, and the Huron Report of 2018; for the figures and other specific information, we relied on the Self- Review report and other data provided by the Academic Senate. We concur with the previous two reports in that “this is a somewhat daunting task, because of the sheer size of the UNEX enterprise”. This review comes at a time of transition. The new Dean Eric Bullard began his appointment in January of 2020, a week before our visit. At this time, neither of the two Associate Dean positions had been filled.
    [Show full text]
  • Protocol Supplementary
    Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf.
    [Show full text]
  • Board Member Profiles 2021
    PALOS VERDES PENINSULA LAND CONSERVANCY BOARD MEMBER PROFILES 2021 OFFICERS Carolynn Petru Occupation: City Administrator/Urban Planner – Retired 2015 President Community Activities: Peninsula Village, Board of Directors and Volunteer Awards & Distinctions: BS Environmental Planning, University of California, Davis; MA Urban Planning, University of California, Los Angeles; American Institute of Certified Planners (1996 – 2015) Rob Kautz Occupation: Principal, HollowayKautz Investments LLC Vice President Community Activities: Los Angeles Police Foundation, Vice Chair 2010-2011, Finance Finance Chair/Treasurer 2002-2010; East Los Angeles College Finance Club speaker/advisor, 2010; Haverford College Alumni Executive Committee 2006-2008; GE Capital Restaurant Leadership Forum, Advisory Board Member 2001-2005; volunteer lecturer on leadership and entrepreneurship, UCLA and Haverford College Awards & Distinctions: LA Business Journal CFO of the Year Finalist, 2010; Robert Half CFO Panel, 2006; National Association for Strategic Planning, Keynote Speaker 2003; National YPO Food and Beverage Roundtable, Keynote Speaker 2003; UCLA Extension/CA Restaurant Association panel 2002; GE Capital’s Innovative Concept of the Year, Award Recipient and Speaker 2002; MBA, Harvard Business School; BA, Economics Diana Bailey Occupation: Attorney – Retired 2015 Secretary Community Activities: Pro Bono, Public Counsel; Volunteer and Member of White Point Community Group and Home Tour, PVPLC; Board of Directors and Volunteer, National Charity League; Executive Board, PTA Rick Wallace Occupation: Certified Public Accountant Treasurer Community Activities: White Point Community Group; LA Biomed Finance Committee; City of Rancho Palos Verdes Finance Advisory Committee 2000-2006; South Bay Lacrosse Association Co-Founder/Chief Financial Officer 2002- 2010; Boy Scout Troop 783 Assistant Scoutmaster 1999-2002 PALOS VERDES PENINSULA LAND CONSERVANCY BOARD MEMBER PROFILES 2021 DIRECTORS Bill Ailor Occupation: Aerospace Fellow, The Aerospace Corp.
    [Show full text]
  • Abstract Book 2014.Indd
    JOURNAL OF PSYCHOPHARMACOLOGY SUPPLEMENT TO VOLUME 28, ISSUE 8, AUGUST 2014 These papers were presented at the Summer Meeting of the BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY 20 – 23 July, Cambridge, UK Indemnity The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting. All contributors completed a Declaration of Interests form when submitting their abstract BAP Office 36 Cambridge Place Hills Road Cambridge CB2 1NS www.bap.org.uk Aii CONTENTS Abstract Book 2014 Abstracts begin on page: SYMPOSIUM 1 Psycho-immunology (S01-S04) A1 SYMPOSIUM 2 Predictors of clinical response in depression (S05-S08) A2 SYMPOSIUM 3 ADHD and obesity: Overlapping neurobiology and development of pharmacological treatments (S09-S12) A3 SYMPOSIUM 4 Cannabinoids in psychiatry: Current understanding and future treatments (S13-S16) A4 SYMPOSIUM 5 Chickens and Eggs: Separating cause and effect in drug addiction (S17-S20) A6 SYMPOSIUM 6 Genetic pathways in psychosis: the road to new treatments? (S21-S24) A7 SYMPOSIUM 7 The adolescent brain – A key stage in the development of psychiatric disorders? (S25-S28) A8 SYMPOSIUM 8 Tobacco addiction in schizophrenia: a translational investigation (S29-S32) A9 SYMPOSIUM 9 Dopamine, impulse control disorders and Parkinson’s disease (S33-S36) A11 POSTERS Cognition (Animals) (MA01-MA14) A12 Drug Dependence (Human) (MB01-MB28)
    [Show full text]
  • 18Spring BA Grad Name Book
    Undergraduate N*me B.ok January 1 – June 30, 2018 Memb,r Governors The Honorable Jim Geringer, Chairman Governor, Wyoming (1995 - 2003) The Honorable Michael O. Leavitt, Chairman, Emeritus Governor, Utah (1993 - 2003) Alaska Guam Montana North Dakota Texas The Honorable The Honorable The Honorable The Honorable The Honorable Bill Walker Eddie Baza Calvo Steve Bullock Doug Burgum Greg Abbott Arizona Hawaii Nebraska Oklahoma Utah The Honorable The Honorable The Honorable The Honorable The Honorable Doug Ducey David Ige Pete Ricketts Mary Fallin Gary R. Herbert California Idaho Nevada Oregon Washington The Honorable The Honorable The Honorable The Honorable The Honorable Jerry Brown C. L. “Butch” Otter Brian Sandoval Kate Brown Jay R. Inslee Colorado Indiana New Mexico South Dakota Wyoming The Honorable The Honorable The Honorable The Honorable The Honorable John Hickenlooper Eric Holcomb Susana Martinez Dennis Daugaard Matt Mead B.ard .f Trustees Chairman The Honorable Jim Geringer Director, Policy & Public Sector, ESRI Governor, State of Wyoming (1995 – 2003) John W. Bluford III Robert Evanson Tammy Johns Dr. Samuel H. Smith President, Emeritus Truman Former President, CEO, Strategy & Talent; President Emeritus, Medical Center; President, McGraw-Hill Former Executive, Manpower Washington State University Bluford Healthcare Education Group Leadership Institute Charles W. Sorenson Joseph Fuller Lenny Mendonca MD, FACS Cole Clark Professor of Management Director Emeritus, President and CEO Emeritus, Executive Director, Higher Practice and Co-Director of McKinsey & Company Intermountain Healthcare Education Client Relations the Managing the Future of Deloitte Services, LP; Work Project, Scott D. Pulsipher Jessie Woolley-Wilson Former Global VP for Harvard Business School President, CEO & President, Education and Research, Western Governors University Dreambox Learning Oracle Corporation The Honorable Gary R.
    [Show full text]
  • Msx-1 Is Suppressed in Bisphosphonate Exposed Jaw Bone
    Msx-1 is suppressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling Falk Wehrhan, Peter Hyckel, Kerstin Amann, Jutta Ries, Philipp Stockmann, Karl Andreas Schlegel, Friedrich Wilhelm Neukam, Emeka Nkenke To cite this version: Falk Wehrhan, Peter Hyckel, Kerstin Amann, Jutta Ries, Philipp Stockmann, et al.. Msx-1 is sup- pressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling. Oral Diseases, Wiley, 2011, 17 (4), pp.433. 10.1111/j.1601-0825.2010.01778.x. hal-00618503 HAL Id: hal-00618503 https://hal.archives-ouvertes.fr/hal-00618503 Submitted on 2 Sep 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Oral Diseases - Manuscript Copy Oral Diseases - Manuscript Copy Msx-1 is suppressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling Journal: Oral Diseases Manuscript ID: ODI-02-10-OM-1552.R1 Manuscript Type: Original Manuscript Date Submitted by the 07-Oct-2010 Author: Complete List of Authors: Wehrhan, Falk; University of Erlangen-Nürnberg,
    [Show full text]
  • Directory of State and Local Government
    DIRECTORY OF STATE AND LOCAL GOVERNMENT Prepared by RESEARCH DIVISION LEGISLATIVE COUNSEL BUREAU 2020 Table of Contents TABLE OF CONTENTS Please refer to the Alphabetical Index to the Directory of State and Local Government for a complete list of agencies. NEVADA STATE GOVERNMENT ORGANIZATIONAL CHART ............................................. D-9 CONGRESSIONAL DELEGATION ............................................................................................. D-13 DIRECTORY OF STATE GOVERNMENT CONSTITUTIONAL OFFICERS: Attorney General ........................................................................................................................ D-15 State Controller ........................................................................................................................... D-19 Governor ..................................................................................................................................... D-20 Lieutenant Governor ................................................................................................................... D-27 Secretary of State ........................................................................................................................ D-28 State Treasurer ............................................................................................................................ D-30 EXECUTIVE BOARDS ................................................................................................................. D-31 NEVADA SYSTEM OF HIGHER EDUCATION
    [Show full text]
  • Efficacy and Safety of Elcatonin in Postmenopausal Women with Osteoporosis: a Systematic Review with Network Meta-Analysis of Randomized Clinical Trials
    Osteoporosis International (2019) 30:1723–1732 https://doi.org/10.1007/s00198-019-04997-6 REVIEW Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials W.-C. Chen1,2 & E.-Y. Lin3 & Y.-N. Kang1,4 Received: 20 November 2018 /Accepted: 21 April 2019 /Published online: 1 May 2019 # International Osteoporosis Foundation and National Osteoporosis Foundation 2019 Abstract Summary The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of elcatonin and safety in combination thera- pies of elcatonin (C-E). Introduction Postmenopausal osteoporosis is an important issue in global aging trends. One treatment of osteoporosis is elcatonin, a kind of calcitonin. However, it has been challenged for long time because of safety. Many trials investigated on this topic, but they were designed differently. Those designs can be categorized in monotherapy of elcatonin (M-E) and C-E. Unfortunately, no synthesized evidence dealt this topic. Methods This study systematically identified target trials from six important databases and only included randomized controlled trial for synthesis. Two investigators assessed quality of eligible trials using the Cochrane Risk of Bias Tool, and they indepen- dently extracted data. Network meta-analysis performed Peto odds ratio (POR, used for dealing with zero cell) or weighted mean difference (WMD, for continuous data) with 95% confidence intervals (CI) and consistency H. Results Sixteen trials recruiting 2754 women with postmenopausal osteoporosis were included in our study. Elcatonin therapies and non-elcatonin medications had comparable fracture rates and bone mineral density change.
    [Show full text]
  • HELD on 17.03.2012:- the NDAC (Analgesics, Anesthetics
    1. RECOMMENDATIONS OF THE NDAC (ANALGESICS, ANESTHETICS AND RHEUMATOLOGY) HELD ON 17.03.2012:- The NDAC (Analgesics, Anesthetics and Rheumatology) deliberated the proposals on 17.03.2012 and recommended the following:- AGENDA NAME OF DRUG RECOMMENDATIONS NO. New Drugs The firm has requested for 3 indications viz mild to moderate pain, dysmenorrhoea and rheumatoid arthritis and osteoarthritis. Committee recommended that the firm should conduct double blind comparative clinical study of Meclofenamate sodium with diclofenac (100mg/day) in 4 sites distributed geographically in the country. 50% of the sites should be in multispeciality hospitals 1 Meclofenamate which have their own Institutional Ethics Sodium Committee. Ethics Committee approval should be from the same area where the site is located. The firm should submit protocol etc. to the office of DCGI and DCGI may issue approval to the study. Based on the data generated, committee may consider their proposal for the three indications proposed. Committee considered the protocol for conduct of local clinical trial in Indian 2 Flupirtine-D- population. However protocol etc. should be Gluconate forwarded to the members for evaluation and recommendation to DCG(I). Committee recommended for approval of the drug in the country subject to submission of CDTL test report to DCG(I). Phase IV clinical trial should be conducted on 500 patients 3 Apixaban within 2 years. Protocol for the Phase IV trial should be submitted to DCG(I) within 3 months of approval of the drug which can be considered and approved by DCG(I). In view of cardiovascular safety concern, committee recommended for giving 4 Dexmedetomidine permission to conduct the study subject to condition that the study should be conducted in subjects aged 8 years and above.
    [Show full text]